DaVita Inc. $DVA Shares Sold by Gabelli Funds LLC

Key Points

• Gabelli Funds LLC reduced its stake in DaVita Inc. by 13.3%, selling 3,793 shares to hold a total of 24,707 shares valued at approximately $3,779,000.
• Insider James O. Hearty sold 2,351 shares at $150 each, decreasing their position by 8.28%, while 90.12% of DaVita's stock is owned by institutional investors.
• Analysts have mixed opinions on DaVita's stock, with one upgrade to "buy" and target prices ranging from $148.00 to $160.00, while the stock currently holds a consensus rating of "Hold."

Gabelli Funds LLC decreased its holdings in shares of DaVita Inc. (NYSE:DVA - Free Report) by 13.3% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 24,707 shares of the company's stock after selling 3,793 shares during the quarter. Gabelli Funds LLC's holdings in DaVita were worth $3,779,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in DVA. UMB Bank n.a. increased its stake in DaVita by 65.5% in the 1st quarter. UMB Bank n.a. now owns 192 shares of the company's stock worth $29,000 after buying an additional 76 shares during the period. Copia Wealth Management bought a new position in DaVita during the 4th quarter worth about $30,000. National Pension Service grew its holdings in DaVita by 74.3% during the 1st quarter. National Pension Service now owns 197 shares of the company's stock worth $30,000 after acquiring an additional 84 shares in the last quarter. Y.D. More Investments Ltd bought a new position in DaVita during the 1st quarter worth about $35,000. Finally, University of Texas Texas AM Investment Management Co. bought a new stake in shares of DaVita in the 1st quarter valued at about $83,000. Hedge funds and other institutional investors own 90.12% of the company's stock.

DaVita Stock Performance

DVA stock traded down $0.94 during trading on Tuesday, reaching $136.82. The company had a trading volume of 1,039,352 shares, compared to its average volume of 857,370. The firm has a 50-day simple moving average of $139.76 and a 200-day simple moving average of $142.29. The company has a market cap of $9.78 billion, a price-to-earnings ratio of 13.45, a price-to-earnings-growth ratio of 0.99 and a beta of 1.13. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.34 and a current ratio of 1.39. DaVita Inc. has a twelve month low of $126.07 and a twelve month high of $179.60.

DaVita (NYSE:DVA - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported $2.95 EPS for the quarter, topping analysts' consensus estimates of $2.70 by $0.25. The company had revenue of $3.38 billion during the quarter, compared to analysts' expectations of $3.36 billion. DaVita had a net margin of 6.35% and a return on equity of 369.39%. DaVita's revenue for the quarter was up 6.1% on a year-over-year basis. During the same period last year, the business earned $2.00 EPS. DaVita has set its FY 2025 guidance at 10.200-11.300 EPS. As a group, sell-side analysts expect that DaVita Inc. will post 10.76 earnings per share for the current year.

Insider Buying and Selling

In other DaVita news, insider James O. Hearty sold 2,351 shares of DaVita stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $150.00, for a total transaction of $352,650.00. Following the completion of the sale, the insider directly owned 26,038 shares in the company, valued at approximately $3,905,700. The trade was a 8.28% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 1.50% of the company's stock.

Analysts Set New Price Targets

A number of analysts have recently weighed in on DVA shares. Barclays lowered their price target on shares of DaVita from $169.00 to $160.00 and set an "equal weight" rating on the stock in a report on Thursday, August 7th. Truist Financial set a $148.00 price target on shares of DaVita in a report on Friday, August 8th. Finally, Wall Street Zen upgraded shares of DaVita from a "hold" rating to a "buy" rating in a report on Friday, August 22nd. Three analysts have rated the stock with a Hold rating, According to MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $164.00.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.